

# National Institutes of Health Update

---

Claire Schuster, MPH  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health

September 2021



National Institute of  
Allergy and  
Infectious Diseases

# FluMos-v1: Universal Influenza Vaccine Candidate

---



A computer-generated image showing HA epitopes arrayed on a nanoparticle  
*Credit: NIAID*

- NIH launches Phase 1 Clinical Trial of FluMos-v1
  - FluMos-v1 is an investigational nanoparticle influenza vaccine designed to provide long-lasting protection against multiple flu virus strains that was developed by NIAID scientists and collaborators at the University of Washington
  - **Purpose:** To assess the safety and immunogenicity of FluMos-v1
  - **Participants:** Up to 35 participants between 18 and 50 years old
  - **Location:** NIH Clinical Center, Bethesda, MD

# Researching COVID to Enhance Recovery (RECOVER)



LATEST UPDATES | ABOUT | FAQs | RESOURCES

Long-term effects of COVID are real. Join the **search for answers.**

Have questions about the long-term health effects of the virus? Start by learning about PASC.

SHARE TO RAISE AWARENESS



<https://recovercovid.org/>



# Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities

---

- Notice of Special Interest (NOSI)
  - **Purpose:** To solicit community-engaged research to:
    - 1) Evaluate intervention strategies (e.g., expand reach, access) to facilitate vaccination uptake in clinical and community contexts; and
    - 2) Address the barriers to increasing reach, access, and uptake of vaccinations among health disparity populations at high risk and likely to experience vaccine hesitancy.
  - **Awards:** For example, National Institute on Minority Health and Health Disparities (NIHMD) recently awarded 5 research grants totaling \$14.5 million over 5 years for these grants, subject to available funds.

<https://nimhd.nih.gov/news-events/news-releases/2021/pr-2021-06-04-vaccine-hesitancy-research.html>



U.S. Department of Health and Human Services

**NIH News**  
National Institutes of Health

# NIH Clinical Trial Evaluating Mixed COVID-19 Vaccine Schedules Begins

National Institute of Allergy and  
Infectious Diseases (NIAID)

<http://www.niaid.nih.gov>

June 1, 2021



Credit: NIH



U.S. Department of Health and Human Services

**NIH News**  
National Institutes of Health


National Institute of Allergy and  
Infectious Diseases (NIAID)

<http://www.niaid.nih.gov>

August 10, 2021

## NIH Launches Study of Third COVID-19 Vaccine Dose in Kidney Transplant Recipients

*Trial Will Assess Antibody Response in  
People Who Did Not Respond to  
Two-Dose Regimen*



Credit: NIAID



# SNIFF Study

- Novavax is conducting a pediatric expansion of its Phase 3 clinical trial for NVX-CoV2373, the company's recombinant protein vaccine candidate against COVID-19.
  - Enrolling up to 3,000 adolescents aged 12-17 across up to 75 sites, including 8 COVID-19 Prevention Network (CoVPN) sites.
- Ancillary nasal swab study called SNIFF (**S**wab your **N**ose to **F**ind in**F**ection) to assess asymptomatic viral shedding of SARS-CoV-2.





U.S. Department of Health and Human Services

**NIH News**  
National Institutes of Health

## **NIH Begins Study of COVID-19 Vaccination During Pregnancy and Postpartum**

***Researchers Will Evaluate Antibody  
Responses in Vaccinated Participants  
and Their Infants***

**National Institute of Allergy and  
Infectious Diseases (NIAID)**

<http://www.niaid.nih.gov>

June 23, 2021



Credit: NIAID